CUE vs. PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, FHTX, TSHA, and CYRX
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry.
Cue Biopharma vs.
Prime Medicine (NYSE:PRME) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Prime Medicine currently has a consensus price target of $13.13, suggesting a potential upside of 343.41%. Cue Biopharma has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Prime Medicine is more favorable than Cue Biopharma.
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by insiders. Comparatively, 12.3% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cue Biopharma has higher revenue and earnings than Prime Medicine. Cue Biopharma is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
Prime Medicine has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.
In the previous week, Prime Medicine had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Prime Medicine and 0 mentions for Cue Biopharma. Prime Medicine's average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.
Cue Biopharma received 124 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 61.11% of users gave Prime Medicine an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote.
Prime Medicine has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Prime Medicine's return on equity of -107.87% beat Cue Biopharma's return on equity.
Summary
Prime Medicine beats Cue Biopharma on 13 of the 17 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CUE) was last updated on 2/22/2025 by MarketBeat.com Staff
